Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$2.22 -0.9%	$1.78	$1.03 ▼ $2.64	$422.71M	1.48	1.69 million shs	2.00 million shs
ERAS Erasca	$1.37 -2.5%	$1.35	$1.01 ▼ $3.45	$419.27M	1.09	1.76 million shs	1.30 million shs
SAGE Sage Therapeutics	$9.12 +0.6%	$7.07	$4.62 ▼ $13.47	$419.56M	0.18	1.27 million shs	4.08 million shs
TBUFF Tribute Pharmaceuticals Canada		$0.00	$0.50 ▼ $1.86	$105.76M	N/A	71,826 shs	50,100 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	-0.89%	-1.33%	+34.55%	+59.71%	+65.67%
ERAS Erasca	-2.85%	-15.22%	+6.23%	-7.77%	-31.75%
SAGE Sage Therapeutics	+0.55%	+30.47%	+32.37%	+13.15%	-19.08%
TBUFF Tribute Pharmaceuticals Canada	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	3.1392 of 5 stars	3.7	3.0	0.0	0.0	2.7	2.5	0.6
ERAS Erasca	2.7394 of 5 stars	3.5	0.0	0.0	0.0	3.6	2.5	1.3
SAGE Sage Therapeutics	2.9918 of 5 stars	2.0	1.0	0.0	4.0	2.9	1.7	0.6
TBUFF Tribute Pharmaceuticals Canada	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.33	Buy	$8.67	290.39% Upside
ERAS Erasca	3.00	Buy	$4.57	234.90% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-2.05% Downside
TBUFF Tribute Pharmaceuticals Canada	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TBUFF, ATAI, SAGE, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/14/2025	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$3.00
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/30/2025	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	1,434.69	N/A	N/A	$0.69 per share	3.22
ERAS Erasca	N/A	N/A	N/A	N/A	$1.50 per share	N/A
SAGE Sage Therapeutics	$41.24M	13.85	N/A	N/A	$7.60 per share	1.20
TBUFF Tribute Pharmaceuticals Canada	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
ERAS Erasca	-$161.65M	-$0.62	N/A	N/A	N/A	N/A	-36.56%	-31.08%	8/11/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
TBUFF Tribute Pharmaceuticals Canada	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest TBUFF, ATAI, SAGE, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/13/2025	Q1 2025	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million
3/20/2025	Q4 2024	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
TBUFF Tribute Pharmaceuticals Canada	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.08	4.07	4.07
ERAS Erasca	N/A	12.35	12.35
SAGE Sage Therapeutics	N/A	9.13	9.13
TBUFF Tribute Pharmaceuticals Canada	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
ERAS Erasca	67.78%
SAGE Sage Therapeutics	99.22%
TBUFF Tribute Pharmaceuticals Canada	N/A

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
ERAS Erasca	14.40%
SAGE Sage Therapeutics	5.50%
TBUFF Tribute Pharmaceuticals Canada	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
ERAS Erasca	120	283.29 million	242.49 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
TBUFF Tribute Pharmaceuticals Canada	N/A	113.72 million	N/A	Not Optionable

TBUFF, ATAI, SAGE, and ERAS Headlines

Recent News About These Companies

Simone Biles pays tribute to husband Jonathan Owens with tiny new tattoo

September 21, 2024 | pagesix.com

Kid Rock's Toby Keith Tribute Concert Broke Taylor Swift's Audience Record?

September 14, 2024 | snopes.com

TRANSFORMERS ONE - Advance Screening & Prize Pack Contest

September 12, 2024 | tribute.ca

Cate Blanchett Calls For Sustainability In Film Industry At TIFF Tribute Awards: “There Is A Moral Imperative To Make This Switch”

September 11, 2024 | deadline.com

Inside the TIFF Tribute Awards: Angelina Jolie Asks for No Photographs and Viggo Mortensen Decries David Cronenberg’s Oscar Snubs

September 11, 2024 | variety.com

TIFF 2024: Tragically Hip series honors beloved Canadian band

September 6, 2024 | reuters.com

Top country stars honor Toby Keith in a new special. Here's how to watch

September 2, 2024 | today.com

‘Survivor’s Remorse’ actress Erica Ash dead at 46: Loni Love, Bow Wow and more pay tribute

July 31, 2024 | pagesix.com

Valeo Pharma Inc. (VPHIF)

May 17, 2024 | finance.yahoo.com

About Tribute.ca

April 1, 2024 | tribute.ca

MacGregor: A Remembrance Day tribute to Canada's Korean War veterans

November 13, 2023 | ottawacitizen.com

Church Under Fire: Canada's War on Christianity - Cast

October 25, 2023 | tribute.ca

Terry Funk dies, aged 79: Pro wrestling industry pays tribute to hardcore icon

August 27, 2023 | sportingnews.com

Ron Canada Biography & Movies

July 23, 2023 | tribute.ca

When her brother died, she wrote a moving tribute on a frisbee. Now, his memory is being shared from one city to the next.

May 2, 2023 | yahoo.com

Alberta tattoo artists pay tribute to laser removal expert who helped people move past trauma

April 29, 2023 | cbc.ca

MITSUBISHI TANABE PHARMA CANADA RECEIVES ENGAGEMENT LETTER FROM PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR RADICAVA® ORAL SUSPENSION

April 27, 2023 | finance.yahoo.com

Humboldt holds tribute five years after deadly bus crash

April 8, 2023 | thestar.com

Paul O’Grady fans break down in tears over Lily Savage’s Blankety Blank tribute episode after shock death

April 3, 2023 | thesun.co.uk

Gamer Crochets Destiny 2 Tribute to Zavalla Actor Lance Reddick

April 3, 2023 | gamerant.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBUFF, ATAI, SAGE, and ERAS Company Descriptions

atai Life Sciences NASDAQ:ATAI

$2.22 -0.02 (-0.89%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$2.20 -0.02 (-0.68%)

As of 04:05 AM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Erasca NASDAQ:ERAS

$1.36 -0.04 (-2.50%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$1.36 -0.01 (-0.66%)

As of 04:05 AM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Sage Therapeutics NASDAQ:SAGE

$9.12 +0.05 (+0.55%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$9.11 -0.01 (-0.11%)

As of 06/17/2025 07:07 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Tribute Pharmaceuticals Canada OTCMKTS:TBUFF

Tribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time